Cargando…

Tigecycline Suppresses the Virulence Factors of Multidrug-Resistant Acinetobacter baumannii Allowing Human Neutrophils to Act

PURPOSE: To determine the ability of human neutrophils to kill multidrug-resistant Acinetobacter baumannii (MDRAB) in the presence of tigecycline (TGC). METHODS: Clinical isolates of MDRAB were cultured with human neutrophils and H(2)O(2) in the presence of TGC. The numbers of viable bacteria, catal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Yoshinori, Hatayama, Nami, Ubagai, Tsuneyuki, Tansho-Nagakawa, Shigeru, Ono, Yasuo, Yoshino, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250330/ https://www.ncbi.nlm.nih.gov/pubmed/35789794 http://dx.doi.org/10.2147/IDR.S368890

Ejemplares similares

Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination
por: Sato, Yoshinori, et al.
Publicado: (2021)

Analysis of Immune Responses in Acinetobacter baumannii-Infected Klotho Knockout Mice: A Mouse Model of Acinetobacter baumannii Infection in Aged Hosts
por: Sato, Yoshinori, et al.
Publicado: (2020)

Pathogenic Bacterium Acinetobacter baumannii Inhibits the Formation of Neutrophil Extracellular Traps by Suppressing Neutrophil Adhesion
por: Kamoshida, Go, et al.
Publicado: (2018)

Histopathological Analysis of Acinetobacter baumannii Lung Infection in a Mouse Model
por: TANSHO-NAGAKAWA, SHIGERU, et al.
Publicado: (2021)

Multidrug-resistant Acinetobacter baumannii resists reactive oxygen species and survives in macrophages
por: Sato, Yoshinori, et al.
Publicado: (2019)

Lipopolysaccharide-Deficient Acinetobacter baumannii Due to Colistin Resistance Is Killed by Neutrophil-Produced Lysozyme
por: Kamoshida, Go, et al.
Publicado: (2020)

Spontaneous formation of neutrophil extracellular traps in serum‐free culture conditions
por: Kamoshida, Go, et al.
Publicado: (2017)

Sub-minimum inhibitory concentrations of colistin and polymyxin B promote Acinetobacter baumannii biofilm formation
por: Sato, Yoshinori, et al.
Publicado: (2018)

Acinetobacter baumannii Lipopolysaccharide Influences Adipokine Expression in 3T3-L1 Adipocytes
por: Unno, Yuka, et al.
Publicado: (2017)

Acinetobacter baumannii LOS Regulate the Expression of Inflammatory Cytokine Genes and Proteins in Human Mast Cells
por: Kikuchi-Ueda, Takane, et al.
Publicado: (2021)

Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection
por: Shin, Jung Ar, et al.
Publicado: (2012)

The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii
por: Li, Liping, et al.
Publicado: (2020)

Resistance mechanisms of tigecycline in Acinetobacter baumannii
por: Sun, Chunli, et al.
Publicado: (2023)

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii
por: Principe, Luigi, et al.
Publicado: (2009)

Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Madadi-Goli, Nahid, et al.
Publicado: (2017)

Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
por: Zhou, Yangang, et al.
Publicado: (2019)

Evaluation of the synergistic effect of a combination of colistin and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Kaya, Ilkem Acar, et al.
Publicado: (2017)

Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia
por: Deng, Yanling, et al.
Publicado: (2022)

Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
por: Ye, Jung-Jr, et al.
Publicado: (2016)

Colistin and tigecycline for management of external ventricular device-related ventriculitis due to multidrug-resistant Acinetobacter baumannii
por: Shrestha, Gentle Sunder, et al.
Publicado: (2016)

Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii
por: Liu, Ben, et al.
Publicado: (2020)

Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-Resistant Acinetobacter baumannii Pneumonia
por: Hu, Guangxue, et al.
Publicado: (2022)

Role of efflux pumps in reduced susceptibility to tigecycline in Acinetobacter baumannii
por: Ardehali, S.H., et al.
Publicado: (2019)

Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii
por: Jo, Jeongwoo, et al.
Publicado: (2021)

Combination Treatment with Intravenous Tigecycline and Intraventricular and Intravenous Colistin in Postoperative Ventriculitis Caused by Multidrug-resistant Acinetobacter baumannii
por: Mizrahi, Cezar J, et al.
Publicado: (2019)

High-Dose Tigecycline in Elderly Patients with Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii in Intensive Care Unit
por: Bai, Xiang-Rong, et al.
Publicado: (2020)

Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii
por: Kumar, Sunil, et al.
Publicado: (2021)

Multidrug-Resistant Acinetobacter baumannii
por: Abbo, Aharon, et al.
Publicado: (2005)

Multidrug-Resistant Acinetobacter baumannii
por: Krcmery, Vladimir, et al.
Publicado: (2007)

Effects of In vivo Emergent Tigecycline Resistance on the Pathogenic Potential of Acinetobacter baumannii
por: Hornsey, Michael, et al.
Publicado: (2018)

COMPARISON OF TWO DIFFERENT METHODS FOR TIGECYCLINE SUSCEPTIBILITY TESTING IN ACINETOBACTER BAUMANNII
por: Bedenić, Branka, et al.
Publicado: (2018)

Characterization of Increased Extracellular Vesicle-Mediated Tigecycline Resistance in Acinetobacter baumannii
por: Cho, Hyejin, et al.
Publicado: (2023)

The Mechanism of Tigecycline Resistance in Acinetobacter baumannii Revealed by Proteomic and Genomic Analysis
por: Liu, Cunwei, et al.
Publicado: (2023)

In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii
por: Park, Gyun Cheol, et al.
Publicado: (2016)

Prolonged and high dosage of tigecycline – successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report
por: Tsachouridou, Olga, et al.
Publicado: (2017)

INVESTIGATION OF TIGECYCLINE SUSCEPTIBILITY OF MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII ISOLATES BY DISC DIFFUSION, AGAR GRADIENT AND BROTH MICRODILUTION TESTS
por: Çalışkan, Emel, et al.
Publicado: (2022)

Comparative analysis of the pathogenicity between multidrug-resistant Acinetobacter baumannii clinical isolates: isolation of highly pathogenic multidrug-resistant A. baumannii and experimental therapeutics with fourth-generation cephalosporin cefozopran
por: Nishida, Satoshi, et al.
Publicado: (2018)

Delirium induced by tigecycline treatment for Acinetobacter baumannii infection: A case report
por: Zheng, Xiaoying, et al.
Publicado: (2019)

Comparative Genomic Analysis of 19 Clinical Isolates of Tigecycline-Resistant Acinetobacter baumannii
por: Liu, Lin, et al.
Publicado: (2020)

Tigecycline Versus Colistin in the Treatment of Carbapenem-resistant Acinetobacter baumannii Complex Osteomyelitis
por: Oliveira, Priscila R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b6eobq37uik8oh1k80ehs34hgj